Back to Browse Journals » Oncolytic Virotherapy » Volume 2

Cell carriers for oncolytic viruses: current challenges and future directions

Authors Roy DG, Bell JC

Received 8 August 2013

Accepted for publication 11 September 2013

Published 10 October 2013 Volume 2013:2 Pages 47—56


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Dominic G Roy,1,2 John C Bell1–3

Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, 2Department of Biochemistry, Immunology and Microbiology, 3Department of Medicine, University of Ottawa, Ottawa, ON, Canada

Abstract: The optimal route for clinical delivery of oncolytic viruses is thought to be systemic intravenous injection; however, the immune system is armed with several highly efficient mechanisms to remove pathogens from the circulatory system. To overcome the challenges faced in trying to delivery oncolytic viruses specifically to tumors via the bloodstream, carrier cells have been investigated to determine their suitability as delivery vehicles for systemic administration of oncolytic viruses. Cell carriers protect viruses from neutralization, one of the most limiting aspects of oncolytic virus interaction with the immune system. Cell carriers can also possess inherent tumor tropism, thus directing the delivery of the virus more specifically to a tumor. With preclinical studies already demonstrating the success and feasibility of this approach with multiple oncolytic viruses, clinical evaluation of cell-mediated delivery of viruses is on the horizon. Meanwhile, ongoing preclinical studies are aimed at identifying new cellular vehicles for oncolytic viruses and improving current promising cell carrier platforms.

Keywords: oncolytic virus, cell carrier, systemic delivery, tumor targeting, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency

Yan M, Zhang KP, Shi YH, Feng LF, Lv L, Li BX

Drug Design, Development and Therapy 2015, 9:5737-5747

Published Date: 22 October 2015

Growth curves and their implications in hand-fed Monk parrots (Myiopsitta monachus)

Petzinger C, Heatley JJ, Bauer JE

Veterinary Medicine: Research and Reports 2015, 6:321-327

Published Date: 15 October 2015

Dendrimer-coupled sonophoresis-mediated transdermal drug-delivery system for diclofenac

Huang B, Dong WJ, Yang GY, Wang W, Ji CH, Zhou FN

Drug Design, Development and Therapy 2015, 9:3867-3876

Published Date: 23 July 2015

Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges

Harnoss JM, Strowitzki MJ, Radhakrishnan P, Platzer LK, Harnoss JC, Hank T, Cai J, Ulrich A, Schneider M

Hypoxia 2015, 3:1-14

Published Date: 30 January 2015

Immune cells: more than simple carriers for systemic delivery of oncolytic viruses

Eisenstein S, Chen SH, Pan PY

Oncolytic Virotherapy 2014, 3:83-91

Published Date: 6 November 2014

Reovirus in cancer therapy: an evidence-based review

Clements D, Helson E, Gujar SA, Lee PWK

Oncolytic Virotherapy 2014, 3:69-82

Published Date: 9 July 2014

Oncolytic virus therapy for cancer

Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL

Oncolytic Virotherapy 2013, 2:31-46

Published Date: 24 September 2013

Oncolytic virotherapy: the questions and the promise

Aurelian L

Oncolytic Virotherapy 2013, 2:19-29

Published Date: 4 June 2013